Compare Walmart Stores Inc (WMT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walmart Stores Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Walmart Stores Inc trades at $106.18 (market cap $841.37B), while State Street SPDR S&P Biotech ETF trades at $159.8. The key difference: Walmart Stores Inc pays a 0.93% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Walmart Stores Inc nearer its low. Which is the better fit depends on your goals.
| WMT | XBI | |
|---|---|---|
Market Cap | $841.37B | — |
Volume | 5,675,288 | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $134.20 | $169.55 |
52-Week Low | $100.41 | $93.43 |
Enterprise Value | $903.60B | — |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Walmart (WMT) trades at $105.83, down 1.22% on the day, amid a bearish technical signal but strong fundamental performance. The company has beaten EPS estimates for three consecutive quarters, with revenue reaching $680.99 billion in 2025 and net income margin improving to 2.85%. Analyst consensus is strongly bullish with a $130.69 price target, though technical indicators show near-term resistance around $107.
The outlook remains positive given consistent earnings beats, expanding profit margins, and strategic initiatives in delivery and AI. Key risks include competitive pressure from Amazon, which recently surpassed Walmart in revenue, and potential margin compression from increased investment. The stock offers a compelling long-term growth story supported by operational efficiency and market dominance.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
